PainReform completes enrollment in second part of Phase 3 trial of PRF-110

PainReform announced a major milestone on the way to registration – the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. In total, 428 patients have been enrolled at eight clinical sites across the U.S. As the study pain score is being tracked for 72 hours, the end of enrollment is generally the end of the clinical part of the study. The Company anticipates reporting top-line results from the Phase 3 trial in the second half of 2024, which will further inform the regulatory submission process and potential commercialization plans. “Completing enrollment in the second part of our Phase 3 trial for PRF-110 is a major achievement for PainReform,” said Dr. Ehud Geller, Executive Chairman of Pain Reform. “We remain highly encouraged by the outlook for PRF-110, based on our clinical trial results thus far, including our Phase 2 trial results and the first part of our Phase 3 trial.”